Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15

Company Overview - Lipocine Inc. (NASDAQ:LPCN) is a clinical-stage biopharmaceutical company focused on developing oral, lipid-based hormone therapies for both men's and women's health, founded in 1997 and headquartered in Salt Lake City, Utah [5]. Clinical Development - On January 20, Lipocine Inc. announced the completion of enrollment and participant dosing in its Phase 3 clinical trial for LPCN 1154, aimed at treating postpartum depression. This milestone is significant as it reduces execution risk ahead of a key clinical readout expected to be reported in early Q2 2026 [4]. - The company anticipates topline safety and efficacy results for LPCN 1154 to be available early in the second quarter of 2026, as stated by CEO Mahesh Patel [4]. Market Potential - H.C. Wainwright raised its price target on Lipocine Inc. to $15 from $7, maintaining a Buy rating, citing the favorable safety profile of LPCN 1154 and the significant unmet need in postpartum depression. The firm views the program as a potential value driver as it progresses through late-stage development [2].